Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded recruitment notice 'No longer looking for participants' and new help/navigation sections including How to Read a Study Record, Common Questions, How to Join a Study, and an updated Intervention/Treatment heading. Old heading 'Intervention / Treatment' and the previous revision label 'v3.5.5' were removed and replaced with the current revision 'v3.6.0'.SummaryDifference0.4%

- Check17 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a new version of the page has been published. This appears to be a small system-level update rather than a change to the study data or its presentation.SummaryDifference0.1%

- Check32 days agoChange DetectedReid Merryman, MD has been added to the investigators list (noted on 2026-05-18 and 2026-05-04) and Philippe Armand, MD, PhD has been removed (noted on 2026-02-12, 2026-01-26, and 2023-07).SummaryDifference0.4%

- Check39 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4, signaling a minor build/version update. This change represents an update to the page's revision history without altering visible content or user interactions.SummaryDifference0.1%

- Check60 days agoChange DetectedThis change updates the page’s system/release revision label from v3.5.2 to v3.5.3, without altering the study record content.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No substantive changes to content or features.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.